Susquehanna International Group’s Denali Therapeutics DNLI Stock Holding History

Susquehanna International Group’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.16M	Buy	45,200 +34,300	+315%	+$705K	﹤0.01%	7817
2026 Q1	$209K	Sell	10,900 -21,100	-66%	-$420K	﹤0.01%	11610
2025 Q4	$528K	Sell	32,000 -44,900	-58%	-$758K	﹤0.01%	8657
2025 Q3	$1.12M	Buy	+76,900	New	+$1.1M	﹤0.01%	7077
2024 Q2	–	Sell	-69,800	Closed	-$1.43M	–	12246
2024 Q1	$1.43M	Buy	69,800 +57,500	+467%	+$1.08M	﹤0.01%	6112
2023 Q4	$264K	Buy	+12,300	New	+$244K	﹤0.01%	10095
2023 Q3	–	Sell	-12,900	Closed	-$381K	–	12182
2023 Q2	$381K	Sell	12,900 -14,300	-53%	-$402K	﹤0.01%	8949
2023 Q1	$627K	Buy	+27,200	New	+$749K	﹤0.01%	8015
2022 Q4	–	Sell	-7,600	Closed	-$233K	–	12668
2022 Q3	$233K	Sell	7,600 -2,900	-28%	-$94.3K	﹤0.01%	10445
2022 Q2	$309K	Sell	10,500 -39,400	-79%	-$1.03M	﹤0.01%	9490
2022 Q1	$1.6M	Sell	49,900 -64,600	-56%	-$2.22M	﹤0.01%	5973
2021 Q4	$5.11M	Buy	114,500 +87,600	+326%	+$4.15M	﹤0.01%	3700
2021 Q3	$1.36M	Buy	26,900 +5,000	+23%	+$282K	﹤0.01%	6750
2021 Q2	$1.72M	Sell	21,900 -32,700	-60%	-$2.02M	﹤0.01%	6279
2021 Q1	$3.12M	Buy	54,600 +38,100	+231%	+$2.55M	﹤0.01%	4872
2020 Q4	$1.38M	Sell	16,500 -31,500	-66%	-$1.9M	﹤0.01%	5927
2020 Q3	$1.72M	Buy	48,000 +34,700	+261%	+$1.05M	﹤0.01%	4910
2020 Q2	$322K	Buy	13,300 +800	+6%	+$18.8K	﹤0.01%	8232
2020 Q1	$219K	Sell	12,500 -22,500	-64%	-$469K	﹤0.01%	8523
2019 Q4	$610K	Sell	35,000 -50,900	-59%	-$847K	﹤0.01%	6541
2019 Q3	$1.32M	Buy	85,900 +70,100	+444%	+$1.34M	﹤0.01%	5104
2019 Q2	$328K	Buy	+15,800	New	+$354K	﹤0.01%	8124
2018 Q3	–	Sell	-12,500	Closed	-$191K	–	9397
2018 Q2	$191K	Buy	+12,500	New	+$236K	﹤0.01%	8651

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group's DNLI Position: Q2 2026 in Review

Susquehanna International Group increased its Denali Therapeutics (DNLI) stake by 144% in Q2 2026, buying an estimated $1.5M and bringing the position to 123,258 shares worth $3.17M. The position accounts for ﹤0.01% of the portfolio, ranked #5514.

Susquehanna International Group first reported a position in DNLI in Q2 2019 and has held it in 28 quarters since. The position peaked at $7.85M in Q1 2023. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Susquehanna International Group held 123,258 shares of Denali Therapeutics worth $3.17M as of Q2 2026.
Susquehanna International Group bought 72,783 Denali Therapeutics shares in Q2 2026, an estimated $1.5M.
Denali Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #5514 holding.
Susquehanna International Group first reported a position in Denali Therapeutics in Q2 2019 and has held it in 28 quarters since.
Susquehanna International Group's Denali Therapeutics position peaked at $7.85M in Q1 2023.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.